Literature DB >> 6736461

Amiodarone: intravenous loading for rapid suppression of complex ventricular arrhythmias.

N D Mostow, L Rakita, T R Vrobel, D Noon, J Blumer.   

Abstract

A major disadvantage of conventional amiodarone therapy is the long delay between initiation of therapy and arrhythmia suppression. In this study, the hypothesis was tested that complex ventricular arrhythmias would be suppressed rapidly by an intravenous amiodarone infusion designed to achieve and maintain a therapeutic serum concentration. Eleven patients were studied. Each underwent a single intravenous dose kinetic study, followed by a two stage infusion of amiodarone that achieved and maintained a serum concentration of 2 to 3 micrograms/ml. In seven patients, arrhythmias during hours 24 to 48 after the infusion were compared with arrhythmias without therapy. Amiodarone therapy reduced episodes of ventricular tachycardia by 85% (p less than 0.01), paired premature ventricular complexes by 74% (p less than 0.01) and premature ventricular complexes by 60% (p less than 0.05). Four patients could not tolerate a control period without therapy because of symptomatic arrhythmias. In three patients, symptomatic arrhythmias were abolished during the 24 hour evaluation period. Two of 11 patients, both with severe left ventricular dysfunction, developed significant hypotension during the loading phase of the infusion. It is concluded that the achievement and maintenance of a therapeutic serum concentration of intravenous amiodarone are effective in the rapid suppression of life-threatening ventricular arrhythmias. Caution should be employed when using large intravenous doses in patients with severely impaired left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736461     DOI: 10.1016/s0735-1097(84)80325-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

Review 1.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

2.  Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats.

Authors:  S J Weir; C T Ueda
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

Review 3.  Clinical pharmacology of antiarrhythmic drugs.

Authors:  A Capucci; D Aschieri; G Q Villani
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

4.  Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells.

Authors:  B Chauffert; D Rey; B Coudert; M Dumas; F Martin
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.